HEALTHSTORY 1117· JUNE 21, 2026

GLP-1 Weight Loss Drug Race Heats Up as Pfizer and Amgen Challenge Novo Nordisk and Eli Lilly

The scramble to compete in the GLP-1 weight loss drug market is intensifying. Pharmaceutical companies Pfizer and Amgen are developing products to take on Novo Nordisk's Wegovy and Eli Lilly's Zepbound

NDNewsDialy Desk2 MIN READPFE · LLY

SOURCE

statnews.com

← PREVIOUS STORY 1116Fentanyl-Linked Chinese Network Ran Fake 'Zksync.jp' Token Scam, Nikkei Reports, With Losses Topping $1 Million NEXT STORY 1118 →Pomerantz Files Class Action Against ServBanc Holdco, IF Bancorp Board Over IROQ Stock

Keep reading

More from the desk.

04HEALTH

U.S. agency commits $62.7 million to build FDA-authorized AI for heart failure care

A federal health research agency is committing $62.7 million to develop artificial intelligence systems designed to help manage heart failure, where heart failure means the heart muscle can no longer pump enough blood to meet the body's…

health2 MIN

58HEALTH

Readers debate doctor credentials, AI in the exam room, and surrogacy in STAT's First Opinion letters

When physician credentials, artificial intelligence in the exam room, and surrogacy generated enough reader mail to warrant a public reply, STAT published the letters. The health and life sciences publ

health1 MIN

79HEALTH

A drug for Angelman syndrome failed its final trial. Researchers say the science is not done.

A late-stage trial for an experimental Angelman syndrome drug came back negative this week, dealing a major blow to patients and to the company behind it. Late-stage, in clinical testing, means the final ro

health2 MIN

Tomorrow · 06:00

Start tomorrow already ahead.

Five stories, a two-minute read, zero noise — the world before your first coffee.

Get the 6AM brief Back to the desk